ALN TTR01

Drug Profile

ALN TTR01

Alternative Names: ALN-TTR01

Latest Information Update: 04 Sep 2013

Price : $50

At a glance

  • Originator Alnylam Pharmaceuticals
  • Class Small interfering RNA
  • Mechanism of Action RNA interference
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Amyloid polyneuropathy
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Amyloidosis

Most Recent Events

  • 28 Aug 2013 Final efficacy data from a phase I trial in Amyloidosis released by Alnylam
  • 06 Aug 2012 Discontinued - Phase-I for Amyloidosis in Sweden (IV)
  • 06 Aug 2012 Discontinued - Phase-I for Amyloidosis in United Kingdom (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top